Observational Study of Treatments for Patients with BRAFV600E Mutant Metastatic Colorectal Cancer in China

What this Trial Is About

Researchers are conducting a real-world, multicenter observational study to better understand metastatic colorectal cancer mCRC patients in China who have the BRAFV600E mutation. Previous studies showed that patients with this mutation tend to have shorter survival times compared to those without it, but data specific to Chinese patients on mutation rates, diagnosis, prognosis, and survival are limited. This study aims to fill those gaps by collecting detailed information on these aspects. The study will observe patients with the BRAFV600E mutation who started treatment for mCRC between October 1, 2020, and October 1, 2025. Treatments involved are those registered for mCRC at the participating centers, but this is a non-interventional study, meaning researchers will not assign treatments but will record existing treatment patterns and regimens. There are no experimental drugs or placebos involved. Participants will be monitored for various outcomes including progression-free survival over 6 months, overall survival over 24 months, and overall response rate at 6 months. Data will be collected retrospectively from multiple centers to capture treatment effectiveness and safety in real-world settings. The study is sponsored by Fudan University and is expected to continue through October 2026.

A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)